Zinfandel Pharmaceuticals, Inc.

Early-stage antisense products targeting Huntington's disease and amyotrophic lateral sclerosis are attracting the attention of big pharma companies, and are the first targets of a just announced broa

Yet another potential Alzheimer's disease therapy, vTv Therapeutics Inc. .'s azeliragon, has failed to show efficacy in top-line data from a late-stage Phase III study, and the company has decided to

The failure of Takeda Pharmaceutical Co. Ltd. / Zinfandel Pharmaceuticals Inc. 's Phase III TOMMORROW study – the first major trial of extremely early Alzheimer's, before symptoms are even appare

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer